Advertisement
Tianjin Chase Sun PharmaceuticalLtd Full Year 2024 Earnings: EPS: CN¥0.02 (vs CN¥0.17 in FY 2023)
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥5.78b (down 5.3% from FY 2023).
- Net income: CN¥51.1m (down 90% from FY 2023).
- Profit margin: 0.9% (down from 8.3% in FY 2023). The decrease in margin was primarily driven by lower revenue.
- EPS: CN¥0.02 (down from CN¥0.17 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tianjin Chase Sun PharmaceuticalLtd Earnings Insights
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are down 3.3% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Tianjin Chase Sun PharmaceuticalLtd that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if Tianjin Chase Sun PharmaceuticalLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300026
Tianjin Chase Sun PharmaceuticalLtd
Engages in the research and development, production, and sale of various pharmaceutical products in China and internationally.
Flawless balance sheet second-rate dividend payer.
Similar Companies
Market Insights
Advertisement
Weekly Picks
TA
Talos on Tesla ·
The "Physical AI" Monopoly – A New Industrial Revolution
Fair Value:US$665.3636.1% undervalued
10 followersusers have followed this narrative
1 commentusers have commented on this narrative
9 likesusers have liked this narrative
MA
Marek_Trnka on CSG ·
Czechoslovak Group - is it really so hot?
Fair Value:€5541.6% undervalued
15 followersusers have followed this narrative
0 commentsusers have commented on this narrative
6 likesusers have liked this narrative
AL
alex30free on Swedencare ·
The Compound Effect: From Acquisition to Integration
Fair Value:SEK 46.2847.8% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Recently Updated Narratives
PI
PittTheYounger on Delta Air Lines ·
Delta loses shine after warning of falling travel demand, but still industry leader
Fair Value:US$63.2117.8% overvalued
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
RA
Ravedigga on Defence Holdings ·
Project Ixian Accelerated Rollout will Drive Valuation Expansion to £0.0150.
Fair Value:UK£0.01516.7% undervalued
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
TO
Tokyo on Siemens ·
EU#5 - From Industrial Giant to the Digital Operating System of the Real World
Fair Value:€319.519.1% undervalued
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
OO
OOO97 on Neo Performance Materials ·
Undervalued Key Player in Magnets/Rare Earth
Fair Value:CA$25.3317.8% undervalued
78 followersusers have followed this narrative
0 commentsusers have commented on this narrative
20 likesusers have liked this narrative
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.886.2% undervalued
58 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
BL
BlackJesus on Adobe ·
The Strategic Revaluation of Adobe: A Critical Analysis of Market Sentiment
Fair Value:US$46042.5% undervalued
34 followersusers have followed this narrative
2 commentsusers have commented on this narrative
22 likesusers have liked this narrative
Trending Discussion
KA
Kalibrator on Ubisoft Entertainment ·
As a gamer, I would not touch this company now. They are hated by the community and have been releasing major flops on their AAA games during the last 5 years (for good reasons). It is true that the valuation is ridiculously low compared to what the licenses are worth, but if the trend continues the value of those will also decline. Management needs to almost make a 180° turnaround to get things right. I agree that a take-private deal before it is too late might be the best option for an investor entering today. We might also see a split sales of the different studios. It is a very risky play, but potentially with high reward.
1
|0
US
User on Tesla ·
When was the last time that Tesla delivered on its promises? Lets go through the list! The last successful would be the Tesla Model 3 which was 2019 with first deliveries 2017. Roadster not shipped. Tesla Cybertruck global roll out failed. They might have a bunch of prototypes (that are being controlled remotely) And you think they'll be able to ship something as complicated as a robot? It's a pure speculation buy.
0
|0